Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cardiovascular

Cardiovascular A17 (P346)Severe hypoglycaemia, cardiovascular outcomes and death: Experience from the ‘Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results’ (LEADER) trialS BAIN1, B Zinman2, SP Marso3, E Christiansen4, S Calanna4, S Rasmussen4, and JB Buse51School of Medicine, University of Swansea, Swansea, UK, 2Lunenfeld–Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Canada, 3Research Medical Center, Kansas City, Missouri, USA, 4Novo Nordisk A/S, Søborg, Denmark, 5University of North Carolina School of Medicine, Chapel Hill, North Carolina, USAAims: In the LEADER cardiovascular (CV) outcomes trial (N = 9,340; NCT01179048), the risk of both CV events and hypoglycaemia was reduced with liraglutide treatment vs placebo, when added to standard of care, in patients with Type 2 diabetes and high risk for CV disease. This post hoc analysis examines potential associations between severe hypoglycaemia and CV events and death.Methods: We analysed time to first major adverse cardiovascular event ([MACE] CV death, non‐fatal myocardial infarction or non‐fatal stroke), CV death and all‐cause death, comparing patients with/without severe hypoglycaemia, and adjusted for different periods of follow‐up and randomised treatment (time‐dependent covariate Cox regression).Results: A total of 267 patients experienced severe hypoglycaemia (liraglutide n = 114, placebo n = 153; rate ratio 0.69; 95% confidence interval [CI] 0.51 to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetic Medicine Wiley

Cardiovascular

Diabetic Medicine , Volume 35 – Jan 1, 2018

Loading next page...
 
/lp/wiley/cardiovascular-T6rBEiU0Ko

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wiley
Copyright
Diabetic Medicine © 2018 Diabetes UK
ISSN
0742-3071
eISSN
1464-5491
DOI
10.1111/dme.3_13570
Publisher site
See Article on Publisher Site

Abstract

A17 (P346)Severe hypoglycaemia, cardiovascular outcomes and death: Experience from the ‘Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results’ (LEADER) trialS BAIN1, B Zinman2, SP Marso3, E Christiansen4, S Calanna4, S Rasmussen4, and JB Buse51School of Medicine, University of Swansea, Swansea, UK, 2Lunenfeld–Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Canada, 3Research Medical Center, Kansas City, Missouri, USA, 4Novo Nordisk A/S, Søborg, Denmark, 5University of North Carolina School of Medicine, Chapel Hill, North Carolina, USAAims: In the LEADER cardiovascular (CV) outcomes trial (N = 9,340; NCT01179048), the risk of both CV events and hypoglycaemia was reduced with liraglutide treatment vs placebo, when added to standard of care, in patients with Type 2 diabetes and high risk for CV disease. This post hoc analysis examines potential associations between severe hypoglycaemia and CV events and death.Methods: We analysed time to first major adverse cardiovascular event ([MACE] CV death, non‐fatal myocardial infarction or non‐fatal stroke), CV death and all‐cause death, comparing patients with/without severe hypoglycaemia, and adjusted for different periods of follow‐up and randomised treatment (time‐dependent covariate Cox regression).Results: A total of 267 patients experienced severe hypoglycaemia (liraglutide n = 114, placebo n = 153; rate ratio 0.69; 95% confidence interval [CI] 0.51 to

Journal

Diabetic MedicineWiley

Published: Jan 1, 2018

There are no references for this article.